Home > Journals > Minerva Stomatologica > Past Issues > Minerva Stomatologica 2010 May;59(5) > Minerva Stomatologica 2010 May;59(5):233-44





A Journal on Dentistry and Maxillofacial Surgery

Official Journal of the Italian Society of Odontostomatology and Maxillofacial Surgery
Indexed/Abstracted in: CAB, EMBASE, Index to Dental Literature, PubMed/MEDLINE, Scopus, Emerging Sources Citation Index




Minerva Stomatologica 2010 May;59(5):233-44


language: English, Italian

Serum anti-p53 antibodies as a diagnostic tumor marker: observations in patients with malignant and premalignant oral cavity lesions

Porrini R. 1, Vercellino V. 1, Rocchetti V. 3, Renò F. 2, Giorda E. 1, Pomato E. 1, Cannas M. 2, Sabbatini M. 2

1 Odontostomatologic Surgery, University of Turin, Turin, Italy; 2 Human Anatomy Laboratory, Department of Clinical and Experimental Medicine, University of Eastern Piedmont, “A. Avogadro”, Novara, Italy; 3 Odontostomatologic Clinic, Department of Clinical and Experimental Medicine, University of Eastern Piedmont “A. Avogadro”, Novara, Italy


AIM: To determine whether serum anti-p53 antibody (p53-Abs) positivity in patients with oral carcinoma corresponds with tumor localization, histological grade, stage, and recurrence.
METHODS: The study population was divided into three groups: controls; patients with a premalignant lesion; and patients with oral squamous cell carcinoma (SCC). The third group was composed of patients attending outpatient services for pathological diagnosis or for follow-up monitoring only. The cancer patients had undergone resective surgery in local anesthesia. Serum p53-Abs levels were measured using a commercial enzyme-linked immunosorbent assay (ELISA) and monitored over a 3-year follow-up period.
RESULTS: Controls and patients with premalignant lesions did not test positive for p53-Abs at ELISA testing. Patients with a malignant lesion tested positive at initial diagnosis when a high histopathological grade lesion was present or localized to the posterior region of the oral cavity. Postoperative serum p53-Abs levels gradually declined until complete seronegativity. Patients with a recurrent tumor tested positive for p53-Abs.
CONCLUSION: Seropositivity for p53-Abs may be associated with histopathological tumor grade, localization, and recurrence. The findings suggest that serum p53-Abs analysis is a useful diagnostic marker for oral SCC.

top of page

Publication History

Cite this article as

Corresponding author e-mail